Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Global Type 1 diabetes market is set to grow at a compound annual growth rate (CAGR) of 13.3 per cent from $2.2 billion in ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Nature gives the first evidence Novo Nordisk's Fiasp (rapid-acting insulin aspart) has been approved by the US FDA for use in insulin pumps! Biotech company SpringWorks Therapeutics plans to raise ...

Sikkim Casino entry fee Fountain Medical Completes $62 Million Series D Financing Novo Nordisk's Fiasp (rapid-acting insulin aspart) has been ap ...

Mahadev Online betting login Another new drug from Ionis, the leader in antisense oligonucleotides, has been approved for marketing in the ...

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes ...

Blessings continue to pour in for the University of the Philippines (UP), and just in time for Christmas. Indeed, aside from the UP Fighting Maroons winning the UAAP Season 87 Men’s Basketball ...

a DB = double-blind, DM = diabetes mellitus, HbA 1c = glycosylated hemoglobin, MC = multicenter, NPH = isophane insulin human, NR = not recorded, OL = open-label, PG = parallel-group, R = randomized.